Is FDA Bipolar or Complicit in Legitimizing Illegal Marketing?

The FDA’s expanded marketing approval process for antipsychotics, highly toxic drugs, is unaffected by evidence uncovered by the US Justice Department showing that the studies submitted by drug manufacturers were often flawed, if not fraudulent. Continue reading →

Senator Grassley Might Leave Finance Committee: A Break For Pharma?

The Hill , a newspaper covering congressional news, reports: "Sen. Chuck Grassley (Iowa) is considering leaving his powerful post as senior Republican on the Finance Committee so that he can become the highest-ranking Republican on the Judiciary panel. To avoid a dramatic . . . Continue reading →

AHRP Letter to Harvard Re: Dr. Biederman’s Research

ahrp_logo.jpg

AHRP proposes a multi-disciplinary team of independent scientists to review ALL of Dr. Joseph Biederman’s publications and supporting documents, including: research protocols, consent forms, and the original (of course, anonymized) data sets with associated code books for all pediatric studies. Continue reading →